00005.001285

PATENT APPLICATION

00003.001203	
IN THE UNITED STATES	PATENT AND TRADEMARK OFFICE
SEP 1 8 2006  Incre Application of:	) : Examiner: Not Yet Assigned
HIROSHI KASE, ET AL.	)
Application No.: 10/565,239	: Group Art Unit: Not Yet Assigned )
Filed: January 19, 2006	; )
For: PHARMACEUTICAL COMPOSITION	: ) : September 14, 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### SUBMISSION OF MISCELLANEOUS PCT FORMS

Sir:

Enclosed to complete the record and for the Examiner's convenience is

Form PCT/IB/338, an English translation of the International Preliminary Report on

Patentability (Form PCT/IB/373) and the Written Opinion of the International Searching

Authority (Form PCT/ISA/237) in the above-identified application. The references

discussed in the Written Opinion are being filed in an Information Disclosure Statement
concurrently herewith.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

Lawrence S. Perry

Attorney for Applicants

Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO 30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

LSP\ac

NY\_Main 591632\_1

#### From the INTERNATIONAL BUREAU

## PCT

NOTIFICATION OF TRANSMITTAL
OF COPIES OF TRANSLATION
OF THE INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY
(CHAPTER I OR CHAPTER II
OF THE PATENT COOPERATION TREATY)

(PCT Rules 44bis.3(c) and 72.2)

KYOWA HAKKO KOGYO CO., LTB. KA-S 6-1, Ohtemachi 1-chome Chiyoda-ku, Tokyo 1008185 JAPON  UP11  JUN 5. 2006

Date of mailing (day/month/year) 26 May 2006 (26.05.2006)

Applicant's or agent's file reference 1595

International application No. PCT/JP2004/010758

IMPORTANT NOTIFICATION

International filing date (day/month/year) 22 July 2004 (22.07.2004)

Applicant

KYOWA HAKKO KOGYO CO., LTD. et al

1. Transmittal of the translation to the applicant.

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter I).

The International Bureau transmits herewith a copy of the English translation of the international preliminary report on patentability (Chapter II).

2. Transmittal of the copy of the translation to the designated or elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following designated or elected Offices requiring such translation:

#### None

The following designated or elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AE, AG, AL, AM, AP, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EA, EC, EE, EG, EP, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability (Chapter II).

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned within the applicable time limit (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Masashi Honda

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 70 10

## PATENT COOPERATION TREATY

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 1595	FOR FURTHER ACTION	See item 4 below	
International application No. PCT/JP2004/010758	International filing date (day/month/year) 22 July 2004 (22.07.2004)	Priority date (day/month/year) 25 July 2003 (25.07.2003)	
International Patent Classification (8t See relevant information in Form I	h edition unless older edition indicated) PCT/ISA/237		
Applicant KYOWA HAKKO KOGYO CO., LT	TD.		

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).				
2.	This REPORT consists of a total of 5 sheets, including this cover sheet.				
٠	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.				
3.	This report contains indications	relating to the following items:			
	Box No. I	Basis of the report			
	Box No. II	Priority			
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
	Box No. IV	Lack of unity of invention			
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			
,	Box No. VI	Certain documents cited			
	Box No. VII	Certain defects in the international application			
	Box No. VIII	Certain observations on the international application			
4.	The International Bureau will conot, except where the applicant date (Rule 44bis .2).	ommunicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but makes an express request under Article 23(2), before the expiration of 30 months from the priority			

	Date of issuance of this report 15 May 2006 (15.05.2006)
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer  Masashi Honda
Facsimile No. +41 22 740 14 35	Telephone No. +41 22 338 70 10

Form PCT/IB/373 (January 2004)

#### PATENT COOPERATION TREATY

TRANSLATION INTERNATIONAL SEARCHING AUTHORITY WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below 1595 International application No. International filing date (day/month/year) Priority date (day/month/year) 25.07.2003 PCT/JP2004/010758 22.07.2004 International Patent Classification (IPC) or both national classification and IPC Applicant KYOWA HAKKO KOGYO CO., LTD. This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/JP Facsimile No. Telephone No.

International application No.
PCT/JP2004/010758

Box No. I	Basis of this opinion						
1. With	h regard to th <b>e language</b> , this opinion has been established on the basis of the international application in the langu L unless otherwise indicated under this item.	age in which it was					
	This opinion has been established on the basis of a translation from the original language into the following language.  which is the language of a translation furnished for the purposes of internat	age ional search (under					
	Rule 12.3 and 23.1(b)).						
2. With	h regard to any nucleotide and/or amino acid sequence disclosed in the international application and necess ention, this opinion has been established on the basis of:	sary to the claimed					
a.	type of material						
	a sequence listing						
	table(s) related to the sequence listing						
b.	format of material						
	in written format						
	in computer readable form						
c.	time of filing/furnishing	•					
	contained in the international application as filed.						
	filed together with the international application in computer readable form.						
	furnished subsequently to this Authority for the purposes of search.						
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.						
4. Add	ditional comments:						
		,					

International application No.

PCT/JP2004/010758

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability							
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industriable have not been examined in respect of:	rially						
the entire international application							
claims Nos. 41							
because:	•						
the said international application, or the said claims Nos. 41 relate to the following subject matter which does not require an international preliminary examination (specify):	-						
Claim 41 includes treatment of the human body by therapy, which is not subject to a search by this International Searching Authority.	Claim 41 includes treatment of the human body by therapy, which is not subject						
the description, claims or drawings (indicate particular elements below) or said claims Nosare so unclear that no meaningful opinion could be formed (specify):							
the claims, or said claims Nos are so inadequately support by the description that no meaningful opinion could be formed.	ted						
no international search report has been established for said claims Nos. 41							
the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Adminis Instructions in that:	rative						
has not been firmished	17						
the written form does not comply with the standard							
the computer readable form has not been furnished							
does not comply with the standard	•						
the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply w technical requirements provided for in Annex C-bis of the Administrative Instructions.	ith the						
See Supplemental Box for further details.							

International application No.
PCT/JP2004/010758

Box N	lo. II	Non-establishment of opinion	n with regard to novelty, inventive step	and industrial applicability			
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:							
		the entire international application	•				
	$\boxtimes$	claims Nos. 41					
be	cause	::					
	the said international application, or the said claims Nos. 41						
		relate to the following subject matter which does not require an international preliminary examination (specify):					
		Claim 41 includes treatment of the human body by therapy, which is not subject					
		to a search by this Interna	tional Searching Authority.				
			•				
		and the second second		· · · · · · · · · · · · · · · · · · ·			
				<del>-</del>			
		•					
				•			
l			dicate particular elements below) or said	claims Nos.			
		are so unclear that no meaningful opini	ion could be formed (specify):				
			•				
	<del></del> -						
[		the claims, or said claims Nos.		are so inadequately supported			
		by the description that no meaningful	opinion could be formed.				
	$\boxtimes$	no international search report has been	established for said claims Nos. 41				
		the nucleotide and/or amino acid sequ Instructions in that:	ence listing does not comply with the sta	ndard provided for in Annex C of the Administrative			
	•	the written form	has not been furnished	•			
		K	does not comply with the standard	1			
		the computer readable form	has not been furnished				
			does not comply with the standard				
		the tables related to the nucleotide an technical requirements provided for in		omputer readable form only, do not comply with the			
		See Supplemental Box for further deta					

International application No.
PCT/JP2004/010758

Box No. V Reasoned statement under Rule citations and explanations suppo			de 43bis.1(a)( porting such	i) with regard to no statement	velty, inventive step or industrial applicability	/; 
1. Statement			-	•		
Novelty	/(N)	Claims	<u>1-40,</u>	42-50		YES
		Claims				NO
Inventiv	ve step (IS)	Claims				YES
		Claims	1-40,	42-50		NO
Industri	ial applicability (IA)	Claims	1-40,	42-50		YES
		Claims				NO

2. Citations and explanations:

Document 1: JP 2928386 B (Kyowa Hakko Kogyo Co., Ltd.) 14 May 1999 Document 2: WO 03/22283 A 1 (Schering Corporation) 20 March 2003

Document 1 cited in the ISR describes a compound represented by the formula (1) of the claimed invention as having an adenosine  $A_{2A}$  receptor antagonist action and being used as an anti-depressant.

Likewise, document 2 describes a medicinal composition comprising an antidepressant in addition to a compound with an adenosine  $A_{2A}$  receptor antagonist action.

Such being the case, combining document 1 and document 2 and including an anti-depressant in the compound represented by the formula (I) which has an adenosine  $A_{2A}$  receptor antagonist action is recognized as being easily carried out by a person skilled in the art.